Promega ADCC Bioassay Effector Cells, F Variant, Propagation Model, 1 each

DESCRIPTION

The ADCC Bioassay F Variant Effector Cells, Propagation Model provides a biologically relevant and specific MOA-based measure of ADCC without the complex workflow and variability inherent in primary cell-based assays.
 

• Allows propagation and banking of the ADCC Bioassay, F Variant, Effector Cells
• Easily quantitate impact of FcγRIIa polymorphism on Fc effector function
• Measure antibody potency and stability

Fc receptor-mediated antibody-dependent cell-mediated cytotoxicity (ADCC) is an important mechanism of action (MOA) by which antibodies target disease cells for elimination. Classic methods used to measure ADCC utilize primary donor peripheral blood mononuclear cells (PBMCs) or purified natural killer (NK) cells that express Fc receptors on their cell surface. Following engagement with the Fc region of a relevant antibody bound to a target disease cell, Fc receptors transduce intracellular signals within the effector cell resulting in elimination of the target cell. These primary cell-based assays are highly variable as a result of donor differences and the requirement for cell culture and expansion. The ADCC Reporter Bioassay provides a biologically relevant and specific MOA-based measure of ADCC without the complex workflow and variability inherent in primary cell-based assays. Specifically, primary donor PBMC or NK cells are replaced with a Jurkat cell stably expressing human FcgammaRIIIa (either the high-affinity V158 or low-affinity F158 receptor) and NFAT-induced luciferase. Importantly, the ADCC Reporter Bioassay demonstrates rank ordering of antibody activity equivalent to classic LDH release ADCC bioassays. The bioassay also can be used to quantify effects of antibody glycosylation on Fc effector function.